Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04486950 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-951 in Healthy Adults
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04486950 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 32 participants.
The verdict
NCT04486950, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
It is hoped that a medicine called TAK-951 will eventually be used to treat nausea and vomiting. Before then, the sponsor needs to understand how the body processes TAK-951 in healthy adults. The main aims of this study are as follows: * To check for side effects from TAK-951 when given at a slow and fast infusion rate. * To learn how much TAK-951 participants can receive without getting side effects from it. Participants will receive a single infusion of either TAK-951 or placebo. In this study, a placebo looks like TAK-951 but does not have any medicine in it. Participants will receive either a low dose or high dose of TAK-951. The infusion will take from 1-3 hours. Participants will stay in the study clinic for about 4 days to receive the study medicine (TAK-951 or placebo) and check for side effects. They will have follow-up visits at the clinic about 2 weeks and 4 weeks after treatment.
Interventions
- DRUG TAK-951
- DRUG TAK-951 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-07-07 |
| Est. Completion | 2021-05-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04486950
The ClinicalTrials.gov registry entry for NCT04486950 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-951 is the first listed.
NCT04486950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04486950 about?
NCT04486950 is a clinical study titled "A Study of TAK-951 in Healthy Adults". It is hoped that a medicine called TAK-951 will eventually be used to treat nausea and vomiting. Before then, the sponsor needs to understand how the body processes TAK-951 in healthy adults. The main aims of this study are as follows: * To check for side effects from TAK-951 when given at a slow ...
What is the current status of trial NCT04486950?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2020-07-07. Estimated completion is 2021-05-27.
What interventions are being tested in trial NCT04486950?
The interventions under investigation include: TAK-951 (DRUG), TAK-951 Placebo (DRUG).
Who is sponsoring clinical trial NCT04486950?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.